Browsing Tag
Halda Therapeutics
3 posts
NYSE: JNJ Q4 earnings rise 49% to $2.10 EPS; oncology and neuroscience lead portfolio momentum
Johnson & Johnson posts $94.2B in 2025 revenue and sets $100.5B FY26 target. Find out what’s driving growth and how STELARA’s erosion could impact momentum.
Halda Therapeutics joins Johnson & Johnson in $3bn cancer drug platform deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B. Find out why its RIPTAC platform could reshape prostate and solid tumor cancer treatment.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.